Tuberculosis Vaccines - state of the art, and novel approaches to vaccine development

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 5-12

  da Costa, Christopher ^a   Walker, Barry ^a   Bonavia, Aurelio ^a  

^a NONE   (United States)

Author keywords

Adjuvant; Mycobacterium; Tuberculosis; Vaccine; Vector

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VACCINE; BCG VACCINE; DAR 901; HEMAGGLUTININ; HEPARIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; VIRUS VECTOR VACCINE;

BCG VACCINATION; CYTOMEGALOVIRUS; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; EXPERIMENTAL MEDICINE; HUMAN; IMMUNOTHERAPY; MUCOSAL ADMINISTRATION; MYCOBACTERIUM VACCAE; NONHUMAN; REVIEW; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; TRENDS; TUBERCULOSIS; VACCINATION;

HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84925236482     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.11.026     Document Type: Review

References (97)

1. World Health Organization. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/. Last accessed November 10, 2014.
2. Kaufmann S.H. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 2010 Apr, 267(4):337-353.
3. Knight G.M., Griffiths U.K., Sumner T., Laurence Y.V., Gheorghe A., Vassall A., et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014 Oct 28, 111(43):15520-15525.
4. Capone S., D'Alise A.M., Ammendola V., Colloca S., Cortese R., Nicosia A., et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013 Apr, 12(4):379-393.
5. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V.S. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant Modified Vaccinia Virus Ankara. The Journal of Immunology 2003, 171:1602-1609.
6. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. The Journal of Immunology 2004, 173:6357-6365.
7. Chen L., Wang J., Zganiacz A., Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infection and Immunity Jan 2004, 72(1):238-246.
8. Giri P.K., Sable S.B., Verma I., Khuller G.K. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunology and Medical Microbiology 2005, 45:87-93.
9. Garcia-Contreras L., Wong Y.-L., Muttil P., Padilla D., Sadoff J., DeRousse J., et al. Immunization by a bacterial aerosol. PNAS March 25 2008, 105(12):4656-4660.
10. White A.D., Sibley L., Dennis M.J., Gooch K., Betts G., Edwards N., et al. Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques. Clin Vaccine Immunol. May 2013, 20(5):663-672.
11. Song K., Bolton D.L., Wei C.J., Wilson R.L., Camp J.V., Bao S., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci U S A. 2010 Dec 21, 107(51):22213-22218.
12. Darrah P.A., Bolton D.L., Lackner A.A., Kaushal D., Aye P.P., Mehra S., et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol. 2014 Aug 15, 193(4):1799-1811.
13. Langermans J.A.M., Andersen P., van Soolingen D., Vervenne R.A.W., Frost P.A., van der Laan T., et al. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci U S A. 2001 September 25, 98(20):11497-11502.
14. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals. 1997 Sep, 25(3):323-338.
15. Low N., Kraemer S., Schneider M., Restrepo A.M. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008 Jan 17, 26(3):383-398.
16. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011 May 26, 473(7348):523-527.
17. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013 May 24; 340(6135): 10.1126/science.1237874. doi:10.1126/science.1237874.
18. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013 October 3, 502(7469). 10.1038/nature12519.
19. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999 Jul 15, 400(6741):269-271.
20. Doherty T.M., Andersen P. Tuberculosis vaccine development. Curr Opin Pulm Med 2002 May, 8(3):183-187.
21. Rook G.A.W., Lowrie D.B., Hernàndez-Pando R. Immunotherapeutics for Tuberculosis in Experimental Animals: Is There a Common Pathway Activated by Effective Protocols?. The Journal of Infectious Diseases 2007, 196:191-198.
22. Okada M., Kita Y., Nakajima T., Kanamaru N., Hashimoto S., Nagasawa T., et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009 May 26, 27(25-26):3267-3270.
23. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine 1996, 2:893-898.
24. Kamath A.T., Hanke T., Briscoe H., Britton W.J. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 1999 Apr, 96(4):511-516.
25. Khera A., Singh R., Shakila H., Rao V., Dhar N., Narayanan P.R., et al. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine. 2005 Dec 1, 23(48-49):5655-5665.
26. Vipond J., Vipond R., Allen-Vercoe E., Clark S.O., Hatch G.J., Gooch K.E., et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine 2006 Sep 11, 24(37-39):6340-6350.
27. Flingai S., Czerwonko M., Goodman J., Kudchodkar S.B., Muthumani K., Weiner D.B. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013, 4:354. 10.3389/fimmu.2013.00354.
28. Bagarazzi M.L., Yan J., Morrow M.P., Shen X., Parker R.L., Lee J.C., et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct 10, 4(155):155ra138. 10.1126/scitranslmed.3004414.
29. Cattamanchi A., Posavad C.M., Wald A., Baine Y., Moses J., Higgins T.J., et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol. 2008 Nov, 15(11):1638-1643.
30. Marshall D.J., San Mateo L.R., Rudnick K.A., McCarthy S.G., Harris M.C., McCauley C., et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother. 2005 Nov, 54(11):1082-1094.
31. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of Plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol. 2007 May, 81(10):5257-5269.
32. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., Weiner D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008 Jan 17, 26(3):440-448.
33. Low L., Mander A., McCann K., Dearnaley D., Tjelle T., Mathiesen J., et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Human Gene Therapy November 2009, 20(11):1269-1278.
34. Vasan S., Hurley A., Schlesinger S.J., Hannaman D., Gardiner D.F., Dugin D.P., et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011, 6(5):e19252. 10.1371/journal.pone.0019252.
35. Yan J., Pankhong P., Shin T.H., Obeng-Adjei N., Morrow M.P., Walters J.N., et al. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res. 2013 Sep, 1(3):179-189.
36. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008 Jun 13, 26(25):3112-3120.
37. Winstone N., Wilson A.J., Morrow G., Boggiano C., Chiuchiolo M.J., Lopez M., et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol. 2011 Sep, 85(18):9578-9587.
38. Jalah R., Patel V., Kulkarni V., Rosati M., Alicea C., Ganneru B., et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother. 2012 Nov 1, 8(11):1620-1629.
39. Kalams S.A., Parker S.D., Elizaga M., Metch B., Edupuganti S., Hural J., et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis. 2013 Sep 1, 208(5):818-829.
40. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001 Jul 12, 412(6843):190-194.
41. Corbière V., Pottier G., Bonkain F., Schepers K., Verscheure V., Lecher S., et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS One 2012, 7(8):e43285. 10.1371/journal.pone.0043285.
42. Stylianou E., Diogo G.R., Pepponi I., van Dolleweerd C., Arias M.A., Locht C., et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur J Immunol. 2014 Feb, 44(2):440-449.
43. Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol. 2009 Mar, 69(3):194-202.
44. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011 Mar 3, 29(11):2100-2109.
45. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 2010 Apr 30, 28(20):3571-3581.
46. Ottenhoff T.H., Doherty T.M., van Dissel J.T., Bang P., Lingnau K., Kromann I., et al. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin. 2010 Dec, 6(12):1007-1015.
47. van Dissel J.T., Joosten S.A., Hoff S.T., Soonawala D., Prins C., Hokey D.A., et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 2014, 10.1016/j.vaccine.2014.10.036.
48. Henson D., van Dissel J., Joosten S., Graves A., Hoff S., Soonawala D., et al. Vaccination with a Hybrid 1 (H1) fusion protein combined with a liposomal adjuvant (CAF01) induced antigen specific T-cells 3 years post vaccination in a human clinical trial. (VAC7P.971). J. Immunol. 2014, 192(1 Supplement). 141.16.
49. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
50. Skeiky Y.A., Dietrich J., Lasco T.M., Stagliano K., Dheenadhayalan V., Goetz M.A., et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010, 28:1084-1093.
51. Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity. PLoS ONE 2012; 7(6):e39909. doi:10.1371/journal.pone.0039909. Last accessed November 10, 2014.
52. Pantaleo G. A phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of BCG and AERAS-404 administered as a prime-boost regimen to HIV-negative, TB-negative, BCG-naïve adults. Paper presented at: TB Vaccines Third Global Forum; 2013 March 25-27; Cape Town, South Africa.
53. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi:10.1126/scitranslmed.3001094. Last accessed November 10, 2014.
54. Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol. 2012 Mar 1, 188(5):2189-2197.
55. Baldwin S.L., Ching L.K., Pine S.O., Moutaftsi M., Lucas E., Vallur A., et al. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J Immunol. 2013 Sep 1, 191(5):2514-2525.
56. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011 Feb, 17(2):189-194.
57. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007 Oct, 6(5):723-739.
58. Skeiky Y.A.W., AldersonMR, Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein. J Immunol 2004, 172:7618-7628.
59. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis-Infected Guinea Pigs. Infec & Immun. 2004, 72:6622-6632.
60. Reed S.G., Coler R.N., Dalemans W., Tand E.V., DeLa Cruz E.C., Basaraba R.J., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. PNAS 2009, 106:2301-2306.
61. + T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013 Apr 19, 31(17):2196-2206.
62. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., et al. Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults. Am J Respir Crit Care Med. Aug 15 2013, 188(4):492-502.
63. Gambillara E, Cavassini M, Audran R, Barbier N, Ofori-Anyinam O, Bollaerts A, et al. The safety and immunogenicity of the candidate M72/AS01E tuberculosis vaccine in HIV-positive adults. Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa. 2009. Abstract LBPEB03.
64. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005 Jan-Mar, 85(1-2):29-38.
65. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE. 2009, 4(4):e5264. 10.1371/journal.pone.0005264.
66. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun. 2009 Aug, 77(8):3364-3373.
67. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004, 10(11):1240-1244. Erratum in: Nat Med. 2004 Dec;10(12):1397.
68. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One. 2007, 2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.
69. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008, 198(4):544-552. Erratum in: J Infect Dis. 2011 Jul;204(1):176. 10.1086/590185.
70. Brookes R.H., Hill P.C., Owiafe P.K., Ibanga H.B., Jeffries D.J., Donkor S.A., et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One. 2008, 3(8):e2921. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/5284a0b6-62a9-484e-80a4-a08c59b3b17c. 10.1371/journal.pone.0002921.
71. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med. 2009, 179(8):724-733.
72. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010, 40(1):279-290. Erratum in: Eur J Immunol. 2011 May;41(5):1501. 10.1002/eji.200939754.
73. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013, 381(9871):1021-1028.
74. Whelan K.T., Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 2009, 4(6):e5934. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/ec8cc565-bf24-4898-b7ba-6e0423d5809f. 10.1371/journal.pone.0005934.
75. Minassian A.M., Rowland R., Beveridge N.E., Poulton I.D., Satti I., Harris S., et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open. 2011, 1(2):e000223. 10.1136/bmjopen-2011-000223.
76. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol. 2007, 37(11):3089-3100. Erratum in: Eur J Immunol. 2011 May;41(5):1501.
77. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun. 2006, 74(8):4634-4643.
78. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One. 2009, 4(6):e5856. 10.1371/journal.pone.0005856.
79. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol. 2005, 174(12):7986-7994.
80. Mu J., Jeyanathan M., Small C.L., Zhang X., Roediger E., Feng X., et al. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol Ther. 2009, 17(6):1093-1100.
81. Smaill F., Jeyanathan M., Smieja M., Medina M.F., Thanthrige-Don N., Zganiacz A., et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med. 2013, 5(205):205ra134. 10.1126/scitranslmed.3006843.
82. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun. 2007, 75(8):4105-4115.
83. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010, 181(12):1407-1417.
84. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30(12):2098-2108.
85. Johnson J.L., Kamya R.M., Okwera A., Loughlin A.M., Nyole S., Hom D.L., et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis 2000, 181(4):1304-1312.
86. Johnson JL1, Nunn A.J., Fourie P.B., Ormerod L.P., Mugerwa R.D., Mwinga A., et al. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Int. J. Tuberc. Lung Dis. 2004, 8(11):1348-1354.
87. Mayo R.E., Stanford J.L. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans. R. Soc. Trop. Med. Hyg 2000, 94(5):563-568.
88. Mwinga A., Nunn A., Ngwira B., Chintu C., Warndorff D., Fine P., et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002, 360(9339):1050-1055.
89. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010 Mar 13, 24(5):675-685.
90. Grode L., Ganoza C.A., Brohm C., Weiner J., Eisele B., Kaufmann S.H. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013 Feb 18, 31(9):1340-1348.
91. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H.E., Recombinant B.C.G. δureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of Type 1 and Type 17 cytokine responses. Journal of Infectious Diseases 2011, 204:1573-1584.
92. Nambiar J.K., Pinto R., Aguilo J.I., Takatsu K., Martin C., Britton W.J., et al. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol. 2012 Feb, 42(2):385-392.
93. Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013 Oct 1, 31(42):4867-4873.
94. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006, 86(3-4):273-289.
95. Vilaplana C., Montané E., Pinto S., Barriocanal A.M., Domenech G., Torres F., et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010, 28(4):1106-1116.
96. Yang X.Y., Chen Q.F., Li Y.P., Wu S.M. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS ONE 2011, 6(9):e23826. 10.1371/journal.pone.0023826.
97. Ma F., Xu W., Chen Y., Lu J., Ding X., Wang Y., et al. Observation of effect and safety on Mycobacterium Vaccae for prevention pulmonary tuberculosis. Chin J Antituberc 2011, 33(10):637-640.